Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
KingstronBio Technology is a clinical-stage medical device and biotechnology company specializing in innovative products for structural heart disease. Founded in 2012 and headquartered in Suzhou, China, the company develops a comprehensive portfolio of next-generation biological heart valves, annuloplasty rings, surgical biopatches, and transcatheter valve systems. KingstronBio leverages its proprietary Micro-Ex™ anti-calcification treatment and AirBo™ dry storage technologies to enhance the durability, biocompatibility, and clinical convenience of its devices. Its product pipeline includes the NMPA-approved Prostyle A® Transcatheter Aortic Valve Replacement (TAVR) system and the ProStyle M® Transcatheter Mitral Valve System, which is currently undergoing national multicenter confirmatory clinical trials.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on KingstronBio Technology.